1000/1000
Hot
Most Recent
Phenaloenones are structurally unique aromatic polyketides that have been reported in both microbial and plant sources. They possess a hydroxy perinaphthenone three-fused-ring system and exhibit diverse bioactivities, such as cytotoxic, antimicrobial, antioxidant, and anti-HIV properties, and tyrosinase, α-glucosidase, lipase, AchE (acetylcholinesterase), indoleamine 2,3-dioxygenase 1, angiotensin-I-converting enzyme, and tyrosine phosphatase inhibition. They have a rich nucleophilic nucleus that has inspired many chemists and biologists to synthesize more of these related derivatives.
Compound Name | Biological Activity | Assay, Organism, or Cell Line | Biological Results | Positive Control | Ref. |
---|---|---|---|---|---|
Paecilomycone A (1) | Tyrosinase inhibition | Colorimetric-microtiter plates/Tyrosinase enzyme | 0.11 mM (IC50) | Kojic acid 0.10 mM (IC50) Arbutin 0.20 mM (IC50) |
[30] |
Paecilomycone B (2) | Tyrosinase inhibition | Colorimetric-microtiter plates/Tyrosinase enzyme | 0.17 mM (IC50) | Kojic acid 0.10 mM (IC50) Arbutin 0.20 mM (IC50) |
[30] |
Paecilomycone C (3) | Tyrosinase inhibition | Colorimetric-microtiter plates/Tyrosinase enzyme | 0.14 mM (IC50) | Kojic acid 0.10 mM (IC50) Arbutin 0.20 mM (IC50) |
[30] |
Aspergillussanone A (5) | Cytotoxicity | Resazurin microplate/KB | 48.4 μM (IC50) | Ellipticine 4.1 μM (IC50) | [31] |
Resazurin microplate/Vero | 34.2 μM (IC50) | Ellipticine 4.5 μM (IC50) | [31] | ||
ent-Peniciherqueinone (8) | Adipogenesis induction | Adiponectin production assay/hBM-MSC(B7) | 57.5 µM (IC50) | Pioglitazone 0.69 µM (IC50) | [32] |
Herqueinone (9) | Antioxidant | DPPH/DPPH• | 0.48 mM (IC50) | Butylated hydroxytoluene 0.11 mM (IC50) | [33] |
Hydroxyl radical scavenging/OH• | 6.34 mM (IC50) | Tannic acid 0.26 mM (IC50) | [33] | ||
Superoxide radical scavenging/O2•− | 4.11 mM (IC50) | Trolox 0.96 mM (IC50) | [33] | ||
Isoherqueinone (12) | Adipogenesis induction | Adiponectin production assay/hBM-MSC(B7) | 39.7 µM (IC50) | Pioglitazone 0.69 µM (IC50) | [32] |
Acetone adduct of a triketone (17) | Anti-inflammatory | Nitric oxide synthase/RAW 264.7 | 3.2 µM (IC50) | AMT 0.2 µM (IC50) | [32] |
(+)-Sclerodin (21) | Cytotoxicity | SRB/U87MG | 55.99 µM (IC50) | Doxorubicin 1.2 µM (IC50) | [34] |
SRB/C6 | 44.65 µM (IC50) | Doxorubicin 0.47 µM (IC50) | [34] | ||
(−)-Sclerodinol (24) | Antimicrobial | Agar dilution/B. cereus | 25.0 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] |
Agar dilution/Proteus species | 50.0 µM (MIC) | Ciprofloxacin 0.78 µM (MIC) | [35] | ||
Agar dilution/M. Phlei | 25.0 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] | ||
Agar dilution/B. subtilis | 12.5 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] | ||
Agar dilution/V. parahemolyticus | 12.5 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] | ||
Agar dilution/MRCNS | 50.0 µM (MIC) | Ciprofloxacin 25.0 µM (MIC) | [35] | ||
Agar dilution/MRSA | 50.0 µM (MIC) | Ciprofloxacin > 50 µM (MIC) | [35] | ||
Bipolarol C (26) | Antibacterial | REMA/B. cereus | 25.0 µg/mL (MIC) | Vancomycin 1.0 µg/mL (MIC) | [36] |
4-Hydroxysclerodin (27) | Anti-angiogenetic | Tube formation assay/HUVECs | 20.9 µM (IC50) | Sunitinib 1.5 µM (IC50) | [32] |
(+)-Sclerodione (28) | Cytotoxicity | SRB/U87MG | 60.93 µM (IC50) | Doxorubicin 1.2 µM (IC50) | [34] |
SRB/C6 | 60.81 µM (IC50) | Doxorubicin 0.47 µM (IC50) | [34] | ||
Antibacterial | Micro-broth dilution/MRSA | 23.0 µg/mL (MIC) | Gentamicin 0.5 µg/mL (MIC) | [34] | |
Micro-broth dilution/E. coli | 35.0 µg/mL (MIC) | Gentamicin 1.0 µg/mL (MIC) | [34] | ||
(−)–Sclerodione (29) | α-Glucosidase inhibition | Colorimetric/α-Glucosidase | 120 µM (IC50) | N-deoxynojirimycin 130.5 µM (IC50) | [37] |
Porcine-lipase inhibition | Colorimetric/Porcine lipase | 1.0 µM (IC50) | Orlistat 9.4 µM (IC50) | [37] | |
(−)-Bipolaride B (30) | Antibacterial | REMA/B. cereus | 25.0 µg/mL (MIC) | Vancomycin 1.0 µg/mL (MIC) | [36] |
Cytotoxicity | REMA/MCF-7 | 79.4 µM (IC50) | Doxorubicin 12.99 µM (IC50) Tamoxifen 19.39 µM (IC50) |
[36] | |
REMA/KB | 96.8 µM (IC50) | Ellipticine 8.32 µM (IC50) Doxorubicin 1.15 µM (IC50) |
[36] | ||
REMA/NCI-H187 | 56.5 µM (IC50) | Ellipticine 9.74 µM (IC50) Doxorubicin 0.19 µM (IC50) |
[36] | ||
Peniciphenalenin H (31) | Antimicrobial | Agar dilution/Proteus species | 50.0 µM (MIC) | Ciprofloxacin 0.78 µM (MIC) | [35] |
Agar dilution/B. subtilis | 25.0 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] | ||
Agar dilution/V. parahemolyticus | 25.0 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] | ||
Agar dilution/MRCNS | 25.0 µM (MIC) | Ciprofloxacin 25.0 µM (MIC) | [35] | ||
Agar dilution/MRSA | 50.0 µM (MIC) | Ciprofloxacin > 50 µM (MIC) | [35] | ||
Bipolarol A (32) | Cytotoxicity | REMA/MCF-7 | 110.4 µM (IC50) | Doxorubicin 12.99 µM (IC50) Tamoxifen 19.39 µM (IC50) |
[36] |
(+)-Scleroderolide (33) | Cytotoxicity | SRB/U87MG | 37.26 µM (IC50) | Doxorubicin 1.2 µM (IC50) | [34] |
SRB/C6 | 23.24 µM (IC50) | Doxorubicin 0.47 µM (IC50) | [34] | ||
Antibacterial | Micro-broth dilution/MRSA | 7.0 µg/mL (MIC) | Gentamicin 0.5 µg/mL (MIC) | [34] | |
Micro-broth dilution/E. coli | 9.0 µg/mL (MIC) | Gentamicin 1.0 µg/mL (MIC) | [34] | ||
(−)–Scleroderolide (34) | α-Glucosidase inhibition | Colorimetric/α-Glucosidase | 48.7 µM (IC50) | N-Deoxynojirimycin 130.5 µM (IC50) | [37] |
porcine-lipase inhibition | Colorimetric/Porcine lipase | 3.4 µM (IC50) | Orlistat 9.4 µM (IC50) | [37] | |
(−)-Bipolaride A (36) | Antibacterial | REMA/B. cereus | 12.5 µg/mL (MIC) | Vancomycin 1.0 µg/mL (MIC) | [36] |
Cytotoxicity | REMA/NCI-H187 | 60.2 µM (IC50) | Ellipticine 9.74 µM (IC50) Doxorubicin 0.19 µM (IC50) |
[36] | |
(−)-Bipolaride E (39) | Antibacterial | REMA/B. cereus | 12.5 µg/mL (MIC) | Vancomycin 1.0 µg/mL (MIC) | [36] |
Cytotoxicity | REMA/MCF-7 | 65.1 µM (IC50) | Doxorubicin 12.99 µM (IC50) Tamoxifen 19.39 µM (IC50) |
[36] | |
REMA/KB | 94.4 µM (IC50) | Ellipticine 8.32 µM (IC50) Doxorubicin 1.15 µM (IC50) |
[36] | ||
REMA/NCI-H187 | 86.9 µM (IC50) | Ellipticine 9.74 µM (IC50) Doxorubicin 0.19 µM (IC50) |
[36] | ||
Bipolarol B (40) | Cytotoxicity | REMA/MCF-7 | 65.3 µM (IC50) | Doxorubicin 12.99 µM (IC50) Tamoxifen 19.39 µM (IC50) |
[36] |
REMA/KB | 52.5 µM (IC50) | Ellipticine 8.32 µM (IC50) Doxorubicin 1.15 µM (IC50) |
[36] | ||
REMA/NCI-H187 | 48.3 µM (IC50) | Ellipticine 9.74 µM (IC50) Doxorubicin 0.19 µM (IC50) |
[36] | ||
Bipolarol D (41) | REMA/MCF-7 | REMA/MCF-7 | 108.7 µM (IC50) | Doxorubicin 12.99 µM (IC50) Tamoxifen 19.39 µM (IC50) |
[36] |
(−)-Bipolaride C (42) | Antibacterial | REMA/B. cereus | 12.5 µg/mL (MIC) | Vancomycin 1.0 µg/mL (MIC) | [36] |
Cytotoxicity | REMA/MCF-7 | 48.9 µM (IC50) | Doxorubicin 12.99 µM (IC50) Tamoxifen 19.39 µM (IC50) |
[36] | |
REMA/KB | 34.4 µM (IC50) | Ellipticine 8.32 µM (IC50) Doxorubicin 1.15 µM (IC50) |
[36] | ||
REMA/NCI-H187 | 59.8 µM (IC50) | Ellipticine 9.74 µM (IC50) Doxorubicin 0.19 µM (IC50) |
[36] | ||
REMA/Vero | 53.1 µM (IC50) | Ellipticine 2.13 µM (IC50) | [36] | ||
Flaviphenalenone A (45) | Cytotoxicity | MTT/A549 | 6.6 µg/mL (IC50) | Doxorubicin HCl 0.2 µg/mL (IC50) | [38] |
MTT/MCF-7 | 10.0 µg/mL (IC50) | Doxorubicin HCl 0.4 µg/mL (IC50) | [38] | ||
Flaviphenalenone B (46) | α-Glucosidase inhibition | Colorimetrically/α-Glucosidase | 94.95 µM (IC50) | Acarbose 685.36 µM (IC50) | [38] |
Flaviphenalenone C (47) | α-Glucosidase inhibition | Colorimetrically/α-Glucosidase | 78.96 µM (IC50) | Acarbose 685.36 µM (IC50) | [38] |
Cytotoxicity | MTT/A549 | 28.5 µg/mL (IC50) | Doxorubicin HCl 0.2 µg/mL (IC50) | [38] | |
MTT/MCF-7 | 50.0 µg/mL (IC50) | Doxorubicin HCl 0.4 µg/mL (IC50) | [38] | ||
Auxarthrone A (49) | Antifungal | Serial dilution/C. neoformans | 3.2 µg/mL (MIC) | Amphotericin B 0.8 µg/mL (MIC) | [39] |
Serial dilution/C. albicans | 3.2 µg/mL (MIC) | Amphotericin B 0.8 µg/mL (MIC) | [39] | ||
Auxarthrone B (50) | Antifungal | Serial dilution/C. neoformans | 12.8 µg/mL (MIC) | Amphotericin B 0.8 µg/mL (MIC) | [39] |
Serial dilution/C. albicans | 25.6 µg/mL (MIC) | Amphotericin B 0.8 µg/mL (MIC) | [39] | ||
Auxarthrone D (51) | Antifungal | Serial dilution/C. neoformans | 6.4 µg/mL (MIC) | Amphotericin B 0.8 µg/mL (MIC) | [39] |
Serial dilution/C. albicans | 6.4 µg/mL (MIC) | Amphotericin B 0.8 µg/mL (MIC) | [39] | ||
Auxarthrone C (52) | Antifungal | Serial dilution/C. neoformans | 25.6 µg/mL (MIC) | Amphotericin B 0.8 µg/mL (MIC) | [39] |
Serial dilution/C. albicans | 51.2 µg/mL (MIC) | Amphotericin B 0.8 µg/mL (MIC) | [39] | ||
FR-901235 (54) | Antifungal | Serial dilution/C. neoformans | 51.2 µg/mL (MIC) | Amphotericin B 0.8 µg/mL (MIC) | [39] |
Serial dilution/C. albicans | 51.2 µg/mL (MIC) | Amphotericin B 0.8 µg/mL (MIC) | [39] | ||
Aspergillussanone D (61) | Antibacterial | Broth microdilution/P. aeruginosa | 38.47 µg/mL (MIC50) | Streptomycin 0.34 µg/mL (MIC50) | [40] |
Broth microdilution/S. aureus | 29.91 µg/mL (MIC50) | Penicillin 0.063 µg/mL (MIC50) | [40] | ||
Aspergillussanone E (62) | Antibacterial | Broth microdilution/E. coli | 7.83 µg/mL (MIC50) | Streptomycin 0.34 µg/mL (MIC50) | [40] |
Aspergillussanone F (63) | Antibacterial | Broth microdilution/P. aeruginosa | 26.56 µg/mL (MIC50) | Streptomycin 0.34 µg/mL (MIC50) | [40] |
Broth microdilution/E. coli | 3.93 µg/mL (MIC50) | Streptomycin 0.25 µg/mL (MIC50) | [40] | ||
Broth microdilution/S. aureus | 16.48 µg/mL (MIC50) | Penicillin 0.063 µg/mL (MIC50) | [40] | ||
Aspergillussanone G (64) | Antibacterial | Broth microdilution/P. aeruginosa | 24.46 µg/mL (MIC50) | Streptomycin 0.34 µg/mL (MIC50) | [40] |
Broth microdilution/S. aureus | 34.66 µg/mL (MIC50) | Penicillin 0.063 µg/mL (MIC50) | [40] | ||
Aspergillussanone H (65) | Antibacterial | Broth microdilution/P. aeruginosa | 8.59 µg/mL (MIC50) | Streptomycin 0.34 µg/mL (MIC50) | [40] |
Broth microdilution/E. coli | 5.87 µg/mL (MIC50) | Streptomycin 0.25 µg/mL (MIC50) | [40] | ||
Aspergillussanone I (66) | Antibacterial | Broth microdilution/P. aeruginosa | 12.00 µg/mL (MIC50) | Streptomycin 0.34 µg/mL (MIC50) | [40] |
Aspergillussanone J (67) | Antibacterial | Broth microdilution/P. aeruginosa | 28.50 µg/mL (MIC50) | Streptomycin 0.34 µg/mL (MIC50) | [40] |
Broth microdilution/E. coli | 5.34 µg/mL (MIC50) | Streptomycin 0.25 µg/mL (MIC50) | [40] | ||
Broth microdilution/S. aureus | 29.87 µg/mL (MIC50) | Penicillin 0.063 µg/mL (MIC50) | [40] | ||
Aspergillussanone K (68) | Antibacterial | Broth microdilution/P. aeruginosa | 6.55 µg/mL (MIC50) | Streptomycin 0.34 µg/mL (MIC50) | [40] |
Broth microdilution/S. aureus | 21.02 µg/mL (MIC50) | Penicillin 0.063 µg/mL (MIC50) | [40] | ||
Aspergillussanone L (69) | Antibacterial | Broth microdilution/P. aeruginosa | 1.87 µg/mL (MIC50) | Streptomycin 0.34 µg/mL (MIC50) | [40] |
Broth microdilution/S. aureus | 2.77 µg/mL (MIC50) | Penicillin 0.063 µg/mL (MIC50) | [40] | ||
Broth microdilution/B. subtilis | 4.80 µg/mL (MIC50) | Penicillin 0.063 µg/mL (MIC50) | [40] | ||
(S)-2-((S,2E,6E,10Z)-14,15-Dihydroxy-11-(hydroxymethyl)-3,7,15-trimethylhexadeca-2,6,10-trien-1-yl)-2,4,6,9-tetrahydroxy-5,7-dimethyl-1H-phenalene-1,3(2H)-dione (70) | Antibacterial | Broth microdilution/P. aeruginosa | 19.07 µg/mL (MIC50) | Streptomycin 0.34 µg/mL (MIC50) | [40] |
Broth microdilution/E. coli | 1.88 µg/mL (MIC50) | Streptomycin 0.25 µg/mL (MIC50) | [40] | ||
Asperphenalenone A (71) | Anti-HIV-1 | Luciferase assay/SupT1 cells | 4.2 µM (IC50) | Lamivudine 0.1 µM (IC50) Efavirenz 0.0004 µM (IC50) |
[41] |
Asperphenalenone B (72) | Anti-HIV-1 | Luciferase assay/SupT1 cells | 32.6 µM (IC50) | Lamivudine 0.1 µM (IC50) Efavirenz 0.0004 µM (IC50) |
[41] |
Asperphenalenone D (74) | Anti-HIV-1 | Luciferase assay/SupT1 cells | 2.4 µM (IC50) | Lamivudine 0.1 µM (IC50) Efavirenz 0.0004 µM (IC50) |
[41] |
Anti-HIV-1 | Luciferase assay/SupT1 cells | 22.1 µM (IC50) | Lamivudine 0.1 µM (IC50) Efavirenz 0.0004 µM (IC50) |
[41] | |
Peniciphenalenin G (83) | Antimicrobial | Agar dilution/B. cereus | 25.0 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] |
Agar dilution/Proteus species | 50.0 µM (MIC) | Ciprofloxacin 0.78 µM (MIC) | [35] | ||
Agar dilution/M. Phlei | 50.0 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] | ||
Agar dilution/B. subtilis | 25.0 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] | ||
Agar dilution/V. Parahemolyticus | 50.0 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] | ||
Agar dilution/MRCNS | 25.0 µM (MIC) | Ciprofloxacin 25.0 µM (MIC) | [35] | ||
Agar dilution/MRSA | 12.5 µM (MIC) | Ciprofloxacin > 50 µM (MIC) | [35] | ||
Coniosclerodione (85) | Antimicrobial | Agar dilution/B. cereus | 25.0 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] |
Agar dilution/Proteus sp. | 25.0 µM (MIC) | Ciprofloxacin 0.78 µM (MIC) | [35] | ||
Agar dilution/M. Phlei | 25.0 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] | ||
Agar dilution/B. subtilis | 12.5 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] | ||
Agar dilution/V. parahemolyticus | 12.5 µM (MIC) | Ciprofloxacin 0.39 µM (MIC) | [35] | ||
Agar dilution/MRCNS | 12.5 µM (MIC) | Ciprofloxacin 25.0 µM (MIC) | [35] | ||
Agar dilution/MRSA | 6.25 µM (MIC) | Ciprofloxacin > 50 µM (MIC) | [35] | ||
Trypethelonamide A (86) | Cytotoxicity | CCK8/RKO | 63.6 µM (IC50) | Taxol 0.05 µM (IC50) | [42] |
5′-Hydroxytrypethelone (87) | Cytotoxicity | CCK8/RKO | 22.6 µM (IC50) | Taxol 0.05 µM (IC50) | [42] |
(+)-8-Hydroxy-7-methoxytrypethelone (88) | Cytotoxicity | CCK8/RKO | 113.5 µM (IC50) | Taxol 0.05 µM (IC50) | [42] |
CCK8/HepG2 | 183.2 µM (IC50) | Taxol 1.0 µM (IC50) | [42] | ||
(+)-Trypethelone (89) | Cytotoxicity | CCK8/RKO | 49.3 µM (IC50) | Taxol 0.05 µM (IC50) | [42] |
(−)-Trypethelone (90) | Cytotoxicity | CCK8/RKO | 30.3 µM (IC50) | Taxol 0.05 µM (IC50) | [42] |
O-Desmethylfunalenone (100) | Antibacterial | REMA/B. subtilis | 265 µM (IC50) | Clotrimazole 0.4 µM (IC50) | [43] |
Cytotoxicity | Resazurin microplate/NS-1 | 70 µM (IC50) | 5-Fluorouracil 4.6 µM (IC50) | [43] | |
Funalenone (101) | hPTP1B1-400 inhibition | Photocolorimetric/hPTP1B1-400 | 6.1 µM (IC50) | Ursolic acid 4.3 µM (IC50) | [44] |
Hispidulone B (103) | Cytotoxicity | MTT/A-549 | 2.71 µM (IC50) | cis-Platinum 8.73 µM (IC50) | [45] |
MTT/Huh7 | 22.93 µM (IC50) | cis-Platinum 5.89 µM (IC50) | [45] | ||
MTT/HeLa | 23.94 µM (IC50) | cis-Platinum 14.68 µM (IC50) | [45] | ||
Aceneoherqueinone A (104) | Angiotensin-I-converting enzyme inhibition | Spectrophotometric/Hippuryl-L-histidyl-L-leucine | 3.10 µM (IC50) | Captopril 9.23 nM (IC50) | [46] |
Aceneoherqueinone B (105) | Angiotensin-I-converting enzyme inhibition | Spectrophotometric/Hippuryl-L-histidyl-L-leucine | 11.28 µM (IC50) | Captopril 9.23 nM (IC50) | [46] |
Erabulenol B (117) | Indoleamine dioxygenase 1 inhibition | ELISA/Indoleamine 2,3-dioxygenase 1 | 13.69 µM (IC50) | Epacadostat 0.015 µM (IC50) | [47] |
Erabulenol C (118) | Indoleamine dioxygenase 1 inhibition | ELISA/Indoleamine 2,3-dioxygenase 1 | 14.38 µM (IC50) | Epacadostat 0.015 µM (IC50) | [47] |
Duclauxin (120) | Antitumor | ELISA/EGFR | 0.95 µM (IC50) | Afatinib 0.0005 µM (IC50) | [48] |
ELISA/CDC25B | 0.75 µM (IC50) | Na3VO4 0.52 µM (IC50) | [48] | ||
Cytotoxicity | Resazurin microplate/NS-1 | 140 µM (IC50) | 5-Fluorouracil 4.6 µM (IC50) | [43] | |
hPTP1B1-400 inhibition | Photocolorimetric/hPTP1B1-400 | 12.7 µM (IC50) | Ursolic acid 26.6 µM (IC50) | [49] | |
Talaromycesone A (121) | Antibacterial | REMA/S. epidermidis | 3.70 µM (IC50) | Chloramphenicol 1.81 µM (IC50) | [50] |
Antibacterial | REMA/MRSA | 5.48 µM (IC50) | Chloramphenicol 2.46 µM (IC50) | [50] | |
AchE inhibition | Modified Ellman’s enzyme/Immunosorbent assay | 7.49 µM (IC50) | Huperzine 11.60 µM (IC50) | [50] | |
Talaromycesone B (122) | Antibacterial | REMA/S. epidermidis | 17.36 µM (IC50) | Chloramphenicol 1.81 µM (IC50) | [50] |
REMA/MRSA | 19.50 µM (IC50) | Chloramphenicol 2.46 µM (IC50) | [50] | ||
hPTP1B1-400 inhibition | Photocolorimetric/hPTP1B1-400 | 82.1 µM (IC50) | Ursolic acid 26.6 µM (IC50) | [49] | |
Bacillisporin A (123) | Antibacterial | Microtiter plate/S. aureus | 5.2 µg/mL (MIC) | Tetracycline 0.05 µg/mL (MIC) | [51] |
Microtiter plate/S. hemolyticus | 9.5 µg/mL (MIC) | Tetracycline 29.2 µg/mL (MIC) | [51] | ||
Microtiter plate/E. faecalis | 2.4 µg/mL (MIC) | Tetracycline 0.4 µg/mL (MIC) | [51] | ||
9a-Epi-bacillisporin E (124) | Antibacterial | Microtiter plate/S. aureus | 29.3 µg/mL (MIC) | Tetracycline 0.05 µg/mL (MIC) | [51] |
Bacillisporin F (125) | Antibacterial | Microtiter plate/S. aureus | 15.6 µg/mL (MIC) | Tetracycline 0.05 µg/mL (MIC) | [51] |
Antitumor | ELISA/EGFR | 4.41 µM (IC50) | Afatinib 0.0005 µM (IC50) | [48] | |
ELISA/CDC25B | 0.40 µM (IC50) | Na3VO4 0.52 µM (IC50) | [48] | ||
Antitumor | ELISA/EGFR | 4.41 µM (IC50) | Afatinib 0.0005 µM (IC50) | [48] | |
ELISA/CDC25B | 0.40 µM (IC50) | Na3VO4 0.52 µM (IC50) | [48] | ||
Bacillisporin G (127) | hPTP1B1-400 inhibition | Photocolorimetric/hPTP1B1-400 | 13.5 µM (IC50) | Ursolic acid 26.6 µM (IC50) | [49] |
Bacillisporin H (128) | Cytotoxicity | MTT/HeLa | 49.5 µM (IC50) | Cisplatin 10.6 µM (IC50) | [51] |
Antibacterial | Microtiter plate/S. aureus | 5.0 µg/mL (MIC) | Tetracycline 0.05 µg/mL (MIC) | [51] | |
Microtiter plate/S. hemolyticus | 20.4 µg/mL (MIC) | Tetracycline 29.2 µg/mL (MIC) | [51] | ||
Verruculosin A (129) | Antitumor | ELISA/EGFR | 0.92 µM (IC50) | Afatinib 0.0005 µM (IC50) | [48] |
Antitumor | ELISA/CDC25B | 0.38 µM (IC50) | Na3VO4 0.52 µM (IC50) | [48] | |
Verruculosin B (130) | Antitumor | ELISA/EGFR | 1.22 µM (IC50) | Afatinib 0.0005 µM (IC50) | [48] |
Xenoclauxin (131) | Antitumor | ELISA/EGFR | 0.24 µM (IC50) | Afatinib 0.0005 µM (IC50) | [48] |
ELISA/CDC25B | 0.26 µM (IC50) | Na3VO4 0.52 µM (IC50) | [48] | ||
hPTP1B1-400 inhibition | Photocolorimetric/hPTP1B1-400 | 21.8 µM (IC50) | Ursolic acid 26.6 µM (IC50) | [49] |